Literature DB >> 21794913

LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation.

C Hurtado1, I Erquiaga, P Aranaz, I Miguéliz, M García-Delgado, F J Novo, J L Vizmanos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21794913     DOI： 10.1016/j.leukres.2011.07.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  10 in total

1.  Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.

Authors:  Ambra Spolverini; Lisa Pieri; Paola Guglielmelli; Alessandro Pancrazzi; Tiziana Fanelli; Chiara Paoli; Alberto Bosi; Ilaria Nichele; Marco Ruggeri; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

Review 2.  The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.

Authors:  N Maslah; B Cassinat; E Verger; J-J Kiladjian; L Velazquez
Journal:  Leukemia       Date:  2017-05-09       Impact factor: 11.528

3.  SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.

Authors:  Maya Koren-Michowitz; Sigal Gery; Takayuki Tabayashi; Dechen Lin; Rocio Alvarez; Arnon Nagler; H Phillip Koeffler
Journal:  Br J Haematol       Date:  2013-04-17       Impact factor: 6.998

Review 4.  Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.

Authors:  Isabelle Plo; Christine Bellanné-Chantelot; Matthieu Mosca; Stefania Mazzi; Caroline Marty; William Vainchenker
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-12       Impact factor: 5.555

5.  The genomic landscape of juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Amaro N Taylor-Weiner; Tiffany Y Chang; Laura C Gelston; Yong-Dong Wang; Tali Mazor; Emilio Esquivel; Ariel Yu; Sara Seepo; Scott Olsen; Mara Rosenberg; Sophie L Archambeault; Ghada Abusin; Kyle Beckman; Patrick A Brown; Michael Briones; Benjamin Carcamo; Todd Cooper; Gary V Dahl; Peter D Emanuel; Mark N Fluchel; Rakesh K Goyal; Robert J Hayashi; Johann Hitzler; Christopher Hugge; Y Lucy Liu; Yoav H Messinger; Donald H Mahoney; Philip Monteleone; Eneida R Nemecek; Philip A Roehrs; Reuven J Schore; Kimo C Stine; Clifford M Takemoto; Jeffrey A Toretsky; Joseph F Costello; Adam B Olshen; Chip Stewart; Yongjin Li; Jing Ma; Robert B Gerbing; Todd A Alonzo; Gad Getz; Tanja Gruber; Todd Golub; Kimberly Stegmaier; Mignon L Loh
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

Review 6.  JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

Authors:  Karoline Gäbler; Iris Behrmann; Claude Haan
Journal:  JAKSTAT       Date:  2013-05-14

7.  LNK (SH2B3): paradoxical effects in ovarian cancer.

Authors:  L-W Ding; Q-Y Sun; D-C Lin; W Chien; N Hattori; X-M Dong; S Gery; M Garg; N B Doan; J W Said; J-F Xiao; H Yang; L-Z Liu; X Meng; R Y-J Huang; K Tang; H P Koeffler
Journal:  Oncogene       Date:  2014-04-07       Impact factor: 9.867

8.  Mutational analysis of SH2B3 in Korean patients with BCR-ABL1 negative myeloproliferative neoplasm.

Authors:  Namhee Kim; In Suk Kim; Chulhun Ludgerus Chang; Eun Yup Lee; Hyung Hoi Kim; Moo Kon Song; Ho Jin Shin; Joo Seop Chung
Journal:  Ann Lab Med       Date:  2016-01       Impact factor: 3.464

9.  Crucial Role of the SH2B1 PH Domain for the Control of Energy Balance.

Authors:  Anabel Flores; Lawrence S Argetsinger; Lukas K J Stadler; Alvaro E Malaga; Paul B Vander; Lauren C DeSantis; Ray M Joe; Joel M Cline; Julia M Keogh; Elana Henning; Ines Barroso; Edson Mendes de Oliveira; Gowri Chandrashekar; Erik S Clutter; Yixin Hu; Jeanne Stuckey; I Sadaf Farooqi; Martin G Myers; Christin Carter-Su
Journal:  Diabetes       Date:  2019-08-22       Impact factor: 9.461

10.  Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.

Authors:  Almudena Aguilera-Diaz; Iria Vazquez; Beñat Ariceta; Amagoia Mañú; Zuriñe Blasco-Iturri; Sara Palomino-Echeverría; María José Larrayoz; Ramón García-Sanz; María Isabel Prieto-Conde; María Del Carmen Chillón; Ana Alfonso-Pierola; Felipe Prosper; Marta Fernandez-Mercado; María José Calasanz
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.